Page last updated: 2024-08-24

emitefur and Neoplasms

emitefur has been researched along with Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Taguchi, T1
Diasio, RB1
Corey, A; Eager, R; Hoff, PM; Nemunaitis, J; Pazdur, R; Sekar, K; Thompson, J; Tkaczuk, K; Twaddell, T1
Hoff, PM; Saad, ED1

Reviews

3 review(s) available for emitefur and Neoplasms

ArticleYear
[Development of fluorinated pyrimidines in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorodeoxyuridylate; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Tegafur

1993
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Drug Evaluation; Enzyme Inhibitors; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Tegafur; Uracil

1999
Other fluorinated pyrimidines in the treatment of solid tumors.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Suppl 2

    Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Pyridines; Tegafur

2001

Trials

1 trial(s) available for emitefur and Neoplasms

ArticleYear
Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms

2000